Selincro
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Nalmefene (Selincro®), an opioid receptor modulator, is approved in Japan, the European Union, and other countries for reducing…
The opioid antagonist nalmefene (selincro®) was approved for alcohol‐related disorders by the European Medicines Agency in 2013…
AIMS
To characterize a contemporaneous cohort of UK general practice patients with alcohol use disorder and describe their…
As part of its single technology appraisal process, the National Institute for Health and Care Excellence (NICE) invited the…
Nalmefene (Selincro®) is a selective opioid receptor antagonist, licensed in April 2014 in Switzerland for the reduction of…
Both Glasgow and medical school were hard drinking gigs. I enjoy alcohol and drink it for its psychoactive effect rather than for…
The opioid system modulator nalmefene (Selincro®) is the first pharmacological therapy to be approved in the EU to reduce alcohol…
The opioid system modulator nalmefene (Selincro®) is approved in the EU for as-needed use to reduce alcohol consumption in…